此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

腹腔镜与开放式 ALPPS 的临床结果和未来肝残余再生反应

2026年9月23日 更新者:Albert Chi Yan Chan、The University of Hong Kong

腹腔镜与开放式 ALPPS 的临床结果和未来肝残余再生反应:一项随机临床试验

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a new surgical procedure that induces rapid liver regeneration in patients with small liver remnant planning for major liver resection. It is a two-staged operation with stage I including portal vein ligation and splitting the right liver away from the left liver. After stage I, the left liver will undergo rapid liver regeneration and the stage II operation can be performed at 7-10 days after stage I operation when the liver remnant reaches an adequate size. In stage II operation, the right liver that contains the tumor is then removed. This surgical procedure was incepted in Germany in 2013 and was later started in Queen Mary Hospital in Hong Kong for the first time in December 2015. The initial indication was mainly for colorectal liver metastasis but due to the relatively high incidence of hepatocellular carcinoma in Hong Kong, HBP surgery team of Queen Mary Hospital has transferred this procedure to be applied for hepatitis-related hepatocellular carcinoma and so far, the centre has cumulated one of the largest single-center experience in the literature. Nonetheless, the usual approach for ALPPS involved open surgery and induced substantial surgical stress to the patient, especially after stage I operation. With the advent of minimally invasive liver surgery in recent years, the team has successfully applied laparoscopic surgery to ALPPS in 2019. Despite the advancement in laparoscopic surgical skills that rendered laparoscopic ALPPS feasible, there is scarcity of data in the literature to evaluate its outcome in comparison with open ALPPS with regard to perioperative recovery and liver regeneration. Hence, the aim of this project is to evaluate the short-term clinical outcomes of laparoscopic ALPPS and the impact of laparoscopy on liver remnant regeneration after ALPPS in a prospective randomised clinical trial setting.

研究概览

详细说明

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has been popularized as an alternative approach for FLR augmentation in recent years. The main indication at the early phase of development of this procedure was bilobar colorectal liver metastasis, or other non-primary liver tumors. Since 2015, HBP surgery team of Queen Mary Hospital has started to transfer this novel approach to treat patients with hepatitis-related hepatocellular carcinoma and small future liver remnant contemplating for major hepatectomy. Despite the initial global enthusiasm to embark on ALPPS, the procedure was criticized for its high postoperative morbidity and mortality rates. However, through the establishment of the international ALPPS registry and familiarization of the procedure, the outcome of ALPPS has been benchmarked and standardized with a mortality rate <4%. The initial experience of ALPPS for HCC was also reported. With cumulative experience, ALPPS has become a safe and effective treatment approach for surgical modulation of insufficient FLR when compared with the conventional approach in the form of portal vein embolization. Nonetheless, ALPPS is a two-stage procedure that commonly involved an open laparotomy. However, the postoperative pain control and speed of recovery after stage I ALPPS would be affected by the substantial surgical stress induced by laparotomy. On the other hand, the rapid development of laparoscopic surgery has rendered laparoscopic liver surgery a much more feasible and safer surgical approach in recent years. As such, minimally invasive approach becomes an attractive option for ALPPS, at least for stage I procedure. Data on the application of laparoscopic ALPPS remained scarce with only one study reported the short-term outcome in a series of 10 patients predominantly affected by colorectal liver metastasis.

Since the short-term postoperative safety profile and underlying intraoperative haemodynamic changes induced by ALPPS for hepatitis-related HCC under conventional open approach was ascertained by our recent study, it is considered that it is the right time to introduce laparoscopy for ALPPS and to compare its clinical outcome with open approach. To date, a total of 4 patients have received laparoscopic ALPPS in the centre.

Recent studies suggested that laparoscopic liver resection may be associated with reduced inflammatory and stress response as compared with open resection as indicated by a reduced expression of inflammatory cytokines such as interleukin-6, tumor necrosis factor. On the other hand, study on liver regeneration after open ALPPS showed an elevated gene expression of IL-6 and TNF as well as increased plasma levels within 24 hours after the procedure when compared with portal vein ligation. It remains uncertain if reduced level of cytokines or inflammatory markers induced by laparoscopy would affect the liver regeneration rate in ALPPS patients and its clinical outcome. Hence, there is a need to clarify this issue in the current project.

研究类型

介入性

注册 (实际的)

20

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Hong Kong、香港
        • The University of Hong Kong

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patients with a diagnosis of malignant liver tumor contemplating for extended right hepatectomy or right trisectionectomy
  2. Patient consent
  3. Age >/= 18
  4. FLR/ESLV </= 30%
  5. Indocyanine green clearance rate at 15 mins : < 18%
  6. Platelet count > 100x10^9/L
  7. Child A cirrhosis (due to hepatitis B/C virus, or alcohol, or autoimmune disease)
  8. American Society of Anaesthesiology score < 3
  9. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

Technical factors eligible for laparoscopic ALPPS

  • single long-segment portal

Exclusion Criteria:

  1. Absence of consent
  2. Decompensated liver disease as indicated by the presence of ascites, varices and hepatic encephalopathy
  3. ECOG performance status >/= 3
  4. Main portal vein thrombosis
  5. FLR/ESLV > 30%

Technical factors not eligible for laparoscopic ALPPS

  • Short-segment right portal vein or early bifurcation of right anterior/posterior portal vein, or other portal vein anomalies
  • Large tumor size with diameter > 5 cm
  • Intolerance to CO2 pneumoperitoneum

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:阶乘赋值
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Laparoscopic ALPPS

Laparoscopic ALPPS procedure

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a surgical procedure that induces rapid liver regeneration in patients with small liver remnant planning for major liver resection. It is a two-staged operation with stage I including portal vein ligation and splitting the right liver away from the left liver. After stage I, the left liver will undergo rapid liver regeneration and the stage II operation can be performed at 7-10 days after stage I operation when the liver remnant reaches an adequate size. In stage II operation, the right liver that contains the tumor is then removed.

其他名称:
  • 阿尔普斯
有源比较器:Open ALPPS

Open ALPPS procedure

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a surgical procedure that induces rapid liver regeneration in patients with small liver remnant planning for major liver resection. It is a two-staged operation with stage I including portal vein ligation and splitting the right liver away from the left liver. After stage I, the left liver will undergo rapid liver regeneration and the stage II operation can be performed at 7-10 days after stage I operation when the liver remnant reaches an adequate size. In stage II operation, the right liver that contains the tumor is then removed.

其他名称:
  • 阿尔普斯

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Amount of future liver remnant volume increment by percentage after stage I ALPPS
大体时间:During hospital stay after stage I ALPPS, an average of 1-2 weeks

Amount of future liver remnant volume increment by percentage after stage I ALPPS

During hospital stay after stage I ALPPS, an average of 1-2 weeks

次要结果测量

结果测量
措施说明
大体时间
Preoperative blood loss during stage 1 ALPPS
大体时间:During hospital stay after stage I ALPPS, an average of 1-2 weeks

Preoperative blood loss during stage 1 ALPPS

During hospital stay after stage I ALPPS, an average of 1-2 weeks
Length of hospital stay after stage 1 ALPPS
大体时间:During hospital stay after stage I ALPPS, an average of 1-2 weeks

Length of hospital stay after stage 1 ALPPS

During hospital stay after stage I ALPPS, an average of 1-2 weeks
Overall morbidity in number and mortality rates in percentage after stage 1 ALPPS
大体时间:During hospital stay after stage I ALPPS, an average of 1-2 weeks

Overall morbidity and mortality rates after stage 1 ALPPS

During hospital stay after stage I ALPPS, an average of 1-2 weeks
Inflammatory markers associated with inflammation and regeneration after stage 1 ALPPS
大体时间:During hospital stay after stage I ALPPS, an average of 1-2 weeks

Inflammatory markers e.g. IL-6 (pg/ml), IL-8 (pg/ml) and TNF-alpha (pg/ml) associated with inflammation and regeneration after stage 1 ALPPS

During hospital stay after stage I ALPPS, an average of 1-2 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Albert Chan、The University of Hong Kong

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年9月2日

初级完成 (实际的)

2023年12月31日

研究完成 (实际的)

2026年8月31日

研究注册日期

首次提交

2020年12月28日

首先提交符合 QC 标准的

2021年4月27日

首次发布 (实际的)

2021年4月30日

研究记录更新

最后更新发布 (实际的)

2026年9月28日

上次提交的符合 QC 标准的更新

2026年9月23日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅